The combined oral administration of neomycin (2 g daily) and clofibrate (2 g daily) reduced significantly serum cholesterol levels in 15 of 16 All patients were ambulatory; their respective diseases were under good control, and 11 of the 16 were working at their regular jobs throughout the study. Medications, other than experimental, were kept constant, and other substances known to influence serum lipid levels were not given. 
management of patients with type II hypercholesterolemia. The multiplicity of the proposed treatments for this condition reflects the magnitude of the difficulties.'0 Most of these patients develop clinical manifestations of atherosclerosis early in life, and the long-term prognosis is poor. In the present study the effect of the individual and of the combined administration of neomycin and clofibrate on serum cholesterol and triglyceride levels was investigated in a group of patients, most of whom had type II hypercholesterolemia and clinical evidence of atherosclerosis.
Methods
Sixteen patients, 10 males and six females, were studied. The age range was from 17 to 62 years. Clinical diagnoses are included in table 1. All patients were ambulatory; their respective diseases were under good control, and 11 of the 16 were working at their regular jobs throughout the study. Medications, other than experimental, were kept constant, and other substances known to influence serum lipid levels were not given. Figure 1 shows the effect of the drugs in patient B.A.
The fall in serum cholesterol due to the administration of neomycin was augmented by the addition of clofibrate to the regimen in five of the 16 patients. After the addition of clofibrate to the administration of neomycin, serum cholesterol levels decreased by an additional 18% in those five subjects, so that the total fall was 29% as compared to control periods. Serum triglyceride levels were further decreased in four of 16 of serum triglycerides was reported during the administration of large daily doses of neomycin (12 g/day) from one laboratory.'3 However, daily oral doses of 2 g by another group of investigators resulted in inconsistent variations of serum glycerides. '4 In the present study serum triglyceride levels were reduced in 25% of the 16 patients studied during the administration of neomycin. It must be emphasized that 14 of our 16 patients had normal triglyceride levels (below 150 mg%) during control periods. Of the two subjects with high initial levels, serum triglycerides were reduced in one.
When clofibrate was added to the administration of neomycin, the level of total serum cholesterol was further reduced in five of the 16 patients. Four of these subjects had type II hypercholesterolemia, and the fall of serum cholesterol levels during the combined administration of the drugs was rather impressive. Control levels of cholesterol were reduced from 334 to 197, 427 to 306, 536 to 299 and 418 to 256 mg%, respectively, in the four patients. In these patients the reduction in serum cholesterol levels was significantly enhanced by the combined therapy, as compared to the individual effect of either of the two drugs ( noted that when the administration of neomycin was discontinued and clofibrate was given alone, serum cholesterol levels increased significantly in 14 of the 16 patients studied.
The exact mechanisms by which neomycin or clofibrate reduces serum lipid levels are unknown. One of the working theories in this laboratory is that neomycin reduces serum cholesterol levels through its action upon the intestinal bacterial flora. This theory was discussed in detail in previous publications.'3 Discussion on the possible lipid-lowering mechanisms of clofibrate was included in several papers published. [4] [5] [6] [7] [8] The theoretical justification of lowering serum cholesterol is the assumption that the amount of cholesterol in the body will be reduced, including cholesterol deposited in atheromas, although specific information on this point is scarce. It has been shown that reduction of serum cholesterol by neomycin coincides with significant reduction in the size of cholesterol pools in the body. 15 There are no similar studies for clofibrate at present.
No major side effects were encountered during the administration of the drugs either singly or in combination. The occurrence of toxicity from parenterally administrated neomycin has been discussed in many reports. However, the daily oral administration of small doses of the drug was well tolerated in our patients and in those of other investigators when the patients were free of renal insufficiency. -3, 13,14 Previous studies from this laboratory showed that the uninterrupted daily oral administration of 0.5 to 2 g of neomycin for as long as 3 years, for cholesterol-lowering purposes was easily feasible and well tolerated by the patients without noteworthy side effects.3 Surprisingly few side effects have been reported from administration of clofibrate. In recent reports the possibility of musculoskeletal abnormalities was described during administration of clofibrate. 16 Properly chosen and monitored patients can receive these drugs to lower serum lipid levels with no serious side effects. It is thus felt that in patients with type II hypercholesterolemia and clinical evidence of arteriosclerosis a trial of combined administration of neomycin and clofibrate is warranted.
